Related Experiment Videos
Valproic acid hepatic fatalities. II. US experience since 1984
F E Dreifuss1, D H Langer, K A Moline
1Department of Neurology, School of Medicine, University of Virginia, Charlottesville 22908.
Neurology
|February 1, 1989
Summary
Physician awareness of valproate risks led to safer prescribing. This resulted in a significant decrease in valproate-associated hepatic fatalities, even as overall usage increased.
Area of Science:
- Pharmacovigilance
- Hepatology
- Clinical Pharmacy
Background:
- Valproate is an anticonvulsant medication with a known risk of hepatic toxicity.
- Previous studies indicated a significant incidence of valproate-associated hepatic fatalities in the US between 1978-1984.
Purpose of the Study:
- To analyze changes in valproate usage patterns and associated hepatic fatalities in the US from 1985-1986.
- To evaluate the impact of altered prescribing practices on valproate-related liver injury.
Main Methods:
- Retrospective analysis of valproate usage and hepatic fatality data from 1985-1986.
- Comparison with data from a previous study period (1978-1984).
- Evaluation of prescribing patterns, including monotherapy vs. polytherapy and patient risk stratification.
Main Results:
- A nearly fivefold decrease in hepatic fatality incidence was observed (0.93/10,000 to 0.20/10,000).
- Valproate use increased significantly, but prescribing shifted towards monotherapy and lower-risk patients.
- Fewer high-risk patients (0-2 years old) received valproate, and no fatalities occurred in patients over 10 years old.
Conclusions:
- Changes in physician prescribing patterns, driven by increased awareness of risk factors, have positively impacted valproate safety.
- The shift towards monotherapy and careful patient selection has led to a reduced rate of valproate-associated hepatic fatality.